Safety and Performance Study of the Legion Porous System in Total Knee Arthroplasty

Multi-center Study of the Safety and Performance of Primary Total Knee Arthroplasty With LEGION™ Porous HA Tibial Baseplates (With and Without Holes) and/or the LEGION™ Porous HA CR Femoral Component in US Centers

The purpose of this research is to collect data on patients that had the Legion Porous HA Tibial Baseplates and/or the Legion Porous HA Femoral component implanted in the past. Smith & Nephew will evaluate the safety and performance of these implants for 10 years post-surgery.

Study Overview

• Status: Active, not recruiting
• Conditions: Total Knee Arthroplasty
• Intervention / Treatment: Device: LEGION Porous HA Tibial Baseplate and/or the LEGION Porous HA CR Femoral Component

• Study Type: Observational
• Enrollment (Actual): 118

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Coon Rapids, Minnesota, United States, 55434
      • Twin Cities Orthopedics
  • Missouri
    • St Louis, Missouri, United States, 63104
      • Saint Louis University Hospital, Dept. of Orthopaedic Surgery

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Maximum of 150 subjects enrolled to obtain a minimum of 150 implanted components:

• Maximum of 75 subjects to obtain a minimum of 75 implanted tibial baseplate components (with or without holes) to attain 30 evaluable baseplates with holes and 30 evaluable baseplates without holes (i.e. a combined total of 60 evaluable implanted baseplate components)
• Maximum of 75 subjects to obtain a minimum of 75 implanted LEGION Porous HA CR Femoral Components to attain 60 evaluable components.

Note: Some subjects may have received both the LEGION Porous HA Tibial Baseplate (with or without holes) and the LEGION Porous HA CR Femoral Component during their TKA procedure.

Description

Inclusion Criteria:

1. Subject received primary TKA with the LEGION Porous HA Tibial Baseplates (either with holes or without holes) and/or the LEGION Porous HA CR Femoral Component, due to degenerative joint disease (primary diagnosis of osteoarthritis, post-traumatic arthritis, or degenerative arthritis).

2. Subject received primary TKA between 24 and 60 months prior to the time of consent.

   Inclusion criteria for prospective follow-up (subjects must meet criteria 1 & 2 from above and criteria 3,4 and 5 below):

3. Subject agrees to consent and to follow the prospective study visit schedule (as defined in the study protocol and informed consent form) by signing the IRB/IEC approved informed consent form.
4. Subject must be available through ten (10) years postoperative follow-up.
5. Subject is able to read, understand, and communicate responses to Patient Reported Outcome assessments in English.

Exclusion Criteria:

Exclusion criteria for retrospective chart review - Any one (1) of the following criteria will disqualify a potential subject from participation in the retrospective chart review:

1. Subject received TKA on the contralateral knee as a revision for a previously failed total or unicondylar knee arthroplasty
2. Subject has ipsilateral hip arthritis resulting in flexion contracture.
3. At the time of enrollment, subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the investigator: Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty; Contralateral primary total knee or unicondylar knee arthroplasty.
4. Subject has a condition that may interfere with the TKA survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, lupus, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease).
5. Subject has a known allergy to one or more of its components of the study device.

6. Subject is entered in another drug, biologic, or device study or has been treated with an investigational product in the past 30 days.

   Exclusion criteria for prospective follow-up - Any one (1) of the criteria from 1-6 above will disqualify a potential subject from participation in the prospective follow-up) as will any one (1) of the below criteria 7, 8 and 9:

7. Subject, in the opinion of the Principal Investigator (PI), has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, drug or alcohol abuse.
8. Subject is known to be at risk for loss to follow-up, or failure to return for scheduled visits.
9. Subject is found to have had a revision of the study device(s).

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Other

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Implant survivorship 10 years post-surgery	10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of life - KOOS JR	Patient Reported Outcomes using Knee Injury and Osteoarthritic Outcome Scores (KOOS JR) questionnaire	10 years
Quality of Life - Forgotten Joint Score (FJS)	Patient Reported Outcomes using Forgotten Joint Score (FJS) questionnaire	10 years
Quality of life - EQ-5D-5L	Patient Reported Outcomes using EuroQol Five Dimensions Questionnaire (EQ-5D - 3L) questionnaire	10 years
Implant survivorship	Implant Survivorship at 5 years defined as the cumulative proportion of knee-implanted components without a revision	5 years
Radiographic findings	X-ray of implanted knee- 3 views (AP, Lateral and Skyline/Merchant) to observe any radiographic findings that may include; Heterotopic ossification, oteolysis, femoral notching, evidence of poly wear, radiolucencies.	10 years

Collaborators and Investigators

• Sponsor: Smith & Nephew, Inc.
• Investigators: Study Chair: Karlie Morgan, Smith & Nephew, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): May 22, 2019
• Primary Completion (Estimated): January 23, 2031
• Study Completion (Estimated): December 31, 2032

Study Registration Dates

• First Submitted: October 19, 2018
• First Submitted That Met QC Criteria: October 24, 2018
• First Posted (Actual): October 25, 2018

Study Record Updates

• Last Update Posted (Actual): April 23, 2026
• Last Update Submitted That Met QC Criteria: April 21, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Legion
• Other Study ID Numbers: LEGHA.PMCF.2018.07

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes